Segments - Sarcoma Drugs Market by Treatment Types (Chemotherapy and Targeted Therapy) and Regions (Asia Pacific, North America, Latin America, Europe, and Middle East & Africa) - Global Industry Analysis, Growth, Share, Size, Trends, and Forecast 2023 - 2031
The global sarcoma drugs market size was valued at USD 1.28 Billion in 2022 and is projected to reach USD 2.76 Billion by 2031, expanding at a CAGR of 8.9% during the forecast period 2023 - 2031.
The growth of the market is attributed to increase in the incidence of soft tissue sarcoma (STS), a rapid increase in the adoption of novel drugs, and the presence of set of automated processes to build and deploy the drugs effectively and efficiently.
Sarcoma refers to a type of cancer that takes place in bone or soft tissues of the body such as fibrous tissue, blood vessels, cartilage, muscle, fat, or other connective tissues. Different types of cancer are present due to the presence of different types of sarcoma. For instance, sarcoma in fats is known as liposarcoma, sarcoma in bone is known as osteosarcoma, and sarcoma in muscle is known as rhabdomyosarcoma.
Sarcoma is anticipated to grow both in children and in adults and its treatment is based on the grade and type of cancer. The treatment of this type of cancer is depended upon how the cancer cell looks like when observed under a microscope and how speedily they are expected to grow and spread. It is reported that two-three people out of 100,000 are diagnosed with soft tissue sarcoma (STS) globally on an annual basis.
According to a report based on the US, 12,715 individuals were diagnosed with soft tissue sarcoma (STS) among which 5,070 death took place in 2017. Nearly 3,373 osteosarcoma cases (sarcoma in bones) were reported among which 1,649 deaths reported. The risk to develop sarcoma is 0.4% in a lifetime and in the age group but 45% of people between the age group of 0-35 years are likely to develop with osteosarcoma (sarcoma in bones) and 21% of soft tissue sarcoma (STS) are diagnosed.
The only approved therapy or treatments available at present are chemotherapy and targeted therapy. Yondelis and Halaven, are two drugs developed by Johnson & Johnson and Eisai respectively for the effective treatment of cancer. Evolution in multiple phase I/II trials is done by checkpoint inhibitors (PD-1/PD-L1).
Effective and safer treatment options are provided to patients when these methods are combined with standard therapies. Presently 12 out of 45 drugs are in the process of development that can be used for the treatment of osteosarcoma (bone sarcoma) and soft tissue sarcoma (STS). Several other antibodies are also under development in phase I and phase II trials.
The report on the global sarcoma drugs market includes an assessment of the market, trends, segments, and regional markets. Overview and dynamics have also been included in the report.
Attributes |
Details |
Report Title |
Sarcoma Drugs Market - Global Industry Analysis, Growth, Share, Size, Trends, and Forecast |
Base Year |
2022 |
Historic Data |
2016–2021 |
Forecast Period |
2023–2031 |
Segmentation |
Treatment Types (Chemotherapy and Targeted Therapy) |
Regional Scope |
Asia Pacific, North America, Latin America, Europe, and Middle East & Africa |
Report Coverage |
Company Share, Market Analysis and Size, Competitive Landscape, Growth Factors, and Trends, and Revenue Forecast |
Key Players Covered in the Report |
Novartis; Eli Lilly, Amgen; Pfizer; Johnson & Johnson; Eisai; Bayer; ytRx; Tracon Pharma; Blueprint Medicines; Arog Pharmaceuticals; Advenchen Laboratories; and Karyopharm Therapeutics |
On the basis of treatment types, the global sarcoma drugs market is bifurcated into chemotherapy and targeted therapy. With the introduction of targeted therapies, the market for treatment for sarcoma has immensely changed over the past few years.
However, the chemotherapy segment is anticipated to dominate the market in the coming years owing to the fact that chemotherapy is highly adopted as a primary treatment procedures. It works throughout the whole body by damaging the cancer cells not only in the place where it originated but also in the place where it spreads.
This fact makes chemotherapy to be the primary method for the treatment of sarcoma. The other therapies or surgery helps to remove the cancer cell or kill it at a particular place.
In terms of regions, the global sarcoma drugs market is classified as Asia Pacific, North America, Latin America, Europe, and Middle East & Africa. The market of North held a key share of the market and the trend is expected to continue in the coming years owing to the wide prevalence of cancer patients and high research activities for development of innovative drugs for the treatment in the region.
Moreover, the presence of the key manufacturers especially in the US and rise in adoption of novel therapies for the treatment play key roles for the regional market growth. Additionally, several activities have been undertaken for the development of therapies that are patient-to-patient customized by key pharmaceutical players in the region.
The global sarcoma drugs market has been segmented on the basis of
Key players competing in the global sarcoma drugs market are Novartis; Eli Lilly, Amgen; Pfizer; Johnson & Johnson; Eisai; Bayer; ytRx; Tracon Pharma; Blueprint Medicines; Arog Pharmaceuticals; Advenchen Laboratories; and Karyopharm Therapeutics. Many of these players have adopted business strategies such as launching new products, introducing new technology, merger, partnership, clinical trials, and production capacity expansion to increase their market position and expand their consumer base globally.